Research Projects
| S. No. | Financial Year | Name of
Faculty (Principal Investigator) |
Name of
Funding agency |
Title of the Project |
| 1. | 2020-2021
|
Dr. Sunil Kohli
|
Serum
Institute of India Private Limited
|
A Phase 2/3, Randomized,
Observer-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine (NmCV-5) and to Compare its Safety and Immunogenicity with that of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age |
| 2. | 2021-2022 | Dr. Sunil Kohli | Indian
Council of Medical Research |
A phase 2/3, observer-blind, randomized, controlled study to determine the
safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with MatrixM1TM adjuvant] in Indian adults |
| 3. | 2021-2022 | Dr. Sunil Kohli
(Co- Investigator)
Dr. Farzana Islam (Co- Investigator) |
Biotechnol ogy Industry
Research Assistance Council (BIRAC) |
Strengthening of a GCP compliant field site in an urban
community in Delhi to accelerate Phase 2/3 COVID19 vaccine trials in India |
| 4. | 2021-2022 | Dr. Sunil Kohli | Serum
Institute of India Private Limited |
Phase II/III, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 Recombinant
Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults aged ≥18 years and children aged 2 to 17 years |
| 5. | 2021-2022 | Dr. Sunil Kohli | Dr. Reddy’s Limited | Randomized, double blind, placebo-controlled parallel group multicenter phase II/III adaptive clinical trial to assess the safety and immunogenicity of Gam-COVID-Vac combined vector vaccine for SARS-Cov2 infection in Indian health
subjects |
| 6. | 2022-2023 | Dr. Sunil Kohli | Serum
Institute of India Private Limited |
Phase III, observer-blind, randomized, controlled study to evaluate the safety and immunogenicity of a booster dose of COVOVAX In Indian adults who have received
primary vaccination against COVID-19 |
| 7. | 2021-2023 | Dr. Sunil Kohli | Gennova Biopharma
ceuticals Limited |
A Prospective, Multicentre, Randomized, Activecontrolled,Observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate the Safety, Tolerability and mmunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy subjects |
| 8. | 2021-2023 | Dr. Sunil Kohli | Bharat
Biotech Internation al Limited |
A Seamless Phase II/III,
Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age |
| 9. | 2024-
Ongoing |
Dr. Sunil Kohli | Serum
Institute of India Private Limited |
A Seamless Phase 1/2,
Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of Dengusiil in Indian Adults and Children ≥ 2 Years of Age (Protocol No.: Dengusiil-02 |
- Phase 3 trial for Meningococcal vaccine (ACYWX conjugate vaccine, NmCV-5) in adult population.
- A longitudinal study to assess immunogenic response and level of anti SARS COV 2 antibodies in person with COVID 19.
- Post COVID sequela in lungs – structural and functional changes
- Effect of extended use of steroids on lungs function in COVID patients.
- Psychiatric manifestations in COVID patients and their relatives.
- Clinical profile of COVID patients admitted at HAHC hospital.
- Impact of COVID on Cardiovascular system.
